Navigation Links
Pearl Therapeutics Raises $15.5 Million in Private Financing
Date:9/6/2007

REDWOOD CITY, Calif., Sept. 6 /PRNewswire/ -- Pearl Therapeutics, Inc., a privately-held company focused on improving the treatment and prevention of widely prevalent respiratory disorders, announced today that the company has raised $15.5 million in its first round of venture capital funding. The financing was co-led by New Leaf Ventures and Clarus Ventures with 5AM Ventures as a major participant. In conjunction with the financing, Kathleen LaPorte, managing director, New Leaf Ventures; Nicholas Simon, managing director, Clarus Ventures; and James W. Young, Ph.D., venture partner, 5AM Ventures, will join Pearl's Board of Directors.

Pearl will deploy these funds to develop innovative products for treatment or prevention of airway diseases in patient populations whose medical needs have not been met by conventional pulmonary drug delivery systems and dosage forms. Pearl has in-licensed a well-developed suite of particle technologies from Nektar Therapeutics which will be leveraged to advance a pipeline of proprietary therapeutics rapidly through development. Nevan Elam, a Nektar senior vice president and head of its Pulmonary Business Unit, has been appointed to Pearl's Board of Directors.

Pearl Therapeutics was co-founded by two former members of Nektar's corporate and product development organizations. Together they bring Pearl more than three decades of experience creating novel pulmonary products. Adrian Smith, president, has led the development and commercialization of technologies and products in the pharmaceutical, medical diagnostic and computer industries for more than 24 years. Starting in 1992 as a one of the first employees of Inhale (now Nektar), he created and directed development of its pulmonary delivery platforms for over a decade in his role as vice president of engineering and technology. More recently until June 2006 he was vice president of corporate development, pulmonary. He drove strategy and planning for Nektar's pulmonary business and championed efforts to apply its technologies to unexplored opportunities. Sarvajna Dwivedi, Ph.D., executive vice president of R&D at Pearl, was most recently director of product development at Nektar. He brings 14 years of extensive pulmonary drug development experience across multiple dosage forms to Pearl, having participated in the inception, development and commercialization of major products in his prior scientific, engineering and management roles at GlaxoWellcome, Dura Pharmaceuticals, Alkermes and Nektar.

"We are very pleased to have received strong support from top-tier and sophisticated biopharmaceutical investors," said Mr. Smith. "These funds will enable us to combine commercially validated particle technologies with the drug delivery, formulation, and product development know-how of the Pearl team to create differentiated products with the potential to broadly and effectively address serious respiratory conditions."

"Pearl Therapeutics incorporates a founding management team with a strong track record of success and expertise in pulmonary drug development including the scale up and commercialization of new products based on proprietary particle technologies. We believe Pearl's products offer the potential for improved treatment of a wider population of patients with chronic respiratory disease," said Dr. Young, executive chairman of the Company, on behalf of the company's investors. "Based on my experience in drug delivery and product development, I am excited to have the opportunity to work with this team and company."

"Adrian and Sarvajna have expert backgrounds in developing pulmonary products and we're pleased that our former colleagues will be exploring new applications with our suite of proven particle technologies," Mr. Elam said.

About Pearl Therapeutics, Inc.

Pearl Therapeutics is focused on developing a pipeline of novel and superior products for chronic respiratory disorders, providing patients with advanced therapeutic options in familiar and well accepted dosage forms. The company has licensed advanced particle technology from Nektar Therapeutics (Nasdaq: NKTR) for developing a series of products in selected therapeutic fields. Founded in 2006, Pearl Therapeutics is privately held, with support from leading investors such as Clarus Ventures, New Leaf Ventures and 5AM Ventures.


'/>"/>
SOURCE Pearl Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Canadian firm buys Proventiv Therapeutics, makes ex-Bone Care exec CEO
2. TomoTherapy raises $223 million in IPO
3. Fusion 2007: CA chief says IT complexity raises risk
4. Inline intellectual property raises legal issues
5. Biotech with Madison ties raises $21M in capital
6. ConjuGon raises $3.3 million to fund clinical trials
7. Nerites raises $1 million to improve medical tech
8. Brady Corp. raises $137 million in public offering
9. aOva Technologies raises $3 million
10. Bush praises Johnson Controls battery tech in Milwaukee visit
11. Anthropology professors blog raises public interest
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... , Feb. 24, 2017  OncoSec Medical Incorporated ("OncoSec") ... will host a Key Opinion Leader event to highlight ... oral and poster presentation at the upcoming 2017 ASCO-SITC ... KOL event will be held in-person and via live ... / 9:00 AM PST at the Lotte New York ...
(Date:2/23/2017)... 23, 2017  MIODx announced today that it ... immunotherapy technologies from the University of California, San ... to monitor a patient for response to immune ... The second license extends the technology with a ... to have an immune-related adverse event (IRAE) from ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... that in a published evaluation of multiple immunoassay-based threat detection technologies by ... Energy Laboratory, PathSensors’ CANARY® biosensor threat detection technology was found to have ...
(Date:2/23/2017)... DIEGO , Feb. 23, 2017 ... research tools, announced the acquisition of GenWay Biotech ... a comprehensive service and product offering for both ... acquisition will facilitate growth and enhance capabilities for ... antibodies, and ELISA assays will nicely complement ASB,s ...
Breaking Biology Technology:
(Date:1/26/2017)... -- Acuity Market Intelligence today released the 2017 "Ten ... characterizes 2017 as a "breakout" year for biometrics ... new understanding of the potential benefits these technologies ... are often perceived as threats to privacy and ... Acuity Market intelligence. "However, taken together these technologies ...
(Date:1/24/2017)... YORK , Jan. 24, 2017 ... study of the laboratory use of nuclear magnetic ... 363 experienced end-users and profiled current practices, developments, ... years, as well as growth and opportunities. These ... Instrument suppliers, NMR instruments, needs and innovation requirements, ...
(Date:1/23/2017)... latest mobile market research from Acuity Market Intelligence reveals ... average price of a biometric smartphone decreased from $849 ... are now 120 sub-$150 models on the market at ... a year ago at an average price of $127. ... Acuity Market Intelligence Principal, "Biometric Smartphones are a global ...
Breaking Biology News(10 mins):